MML Investors Services LLC bought a new position in shares of Cambrex Co. (NYSE:CBM) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,258 shares of the biotechnology company’s stock, valued at approximately $204,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of CBM. Brown Advisory Inc. increased its holdings in Cambrex by 454.1% during the fourth quarter. Brown Advisory Inc. now owns 895,240 shares of the biotechnology company’s stock worth $42,972,000 after buying an additional 733,663 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Cambrex during the fourth quarter worth $22,203,000. Boston Partners increased its holdings in Cambrex by 118.5% during the fourth quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock worth $34,069,000 after buying an additional 384,897 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in Cambrex during the fourth quarter worth $9,780,000. Finally, Mackenzie Financial Corp acquired a new position in Cambrex during the fourth quarter worth $9,403,000.
CBM stock opened at $51.50 on Friday. Cambrex Co. has a 52-week low of $42.55 and a 52-week high of $62.95. The company has a market cap of $1,754.02, a price-to-earnings ratio of 16.78, a price-to-earnings-growth ratio of 1.27 and a beta of 2.38.
CBM has been the topic of a number of recent analyst reports. William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Longbow Research cut shares of Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $60.00.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.